Letters, Testimony & Comments

March 24, 2006
Comments to the USTR touching on Intellectual Property Rights, Biosafety Protocol Implementation, Adventitious Presence, and Labeling.
March 1, 2006
BIO's comments regarding the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; Section 1013: Identification of Priority Topics for Effective Health Care Research
March 1, 2006
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify before the Advisory Panel on Ambulatory Payment Classifications (the APC Panel). BIO is the largest trade organization to serve and represent the biotechnology...
February 27, 2006
BIO's Comments on Authoritative Drug Compendia That May Be Used in Determining Medically Accepted Indications of Drugs and Biologicals Used in an Anti-Cancer Chemotherapeutic Regimen.
February 14, 2006
This morning at breakfast I noted that this year's conference is our most well-attended yet. In just the past few hours, the numbers have continued to grow. We now have 1684 participants registered and still counting - even in the midst of a record-...
February 7, 2006
Supporting the Genetic Information Nondiscrimination Act (GINA)
January 20, 2006
BIO's Comments on the Centers for Medicare and Medicaid Servicesí interim final rule regarding exclusion of vendor purchases made under the Competitive Acquisition Program (CAP) for outpatient drugs and biologicals under Part B.
January 6, 2006
To United States Pharmacopeia
December 23, 2005
BIO's Comments on the Centers for Medicare and Medicaid Services' final rule regarding revisions to payment policies under the Medicare physician fee schedule and certain provisions related to the Competitive Acquisition Program.
December 14, 2005
BIOís comments on Noridian Admistrative Services draft LCD regarding drugs and their covered diagnosis.
December 13, 2005
BIO's comments on the Office of Inspector General's proposed Rule regarding new Safe Harbors for e-prescribing